Multinational drug makers are speeding up the arrival of cutting‑edge medicines in China, especially in Shanghai’s Pudong district. Boehringer Ingelheim says its Chinese operations are now fully woven into its global research network, with several breakthrough drugs debuting worldwide or receiving simultaneous approval in China. By 2026 the company expects to launch two new medicines locally, cutting the usual lag between Europe, the U.S., and China to almost zero. In fact, its treatment for progressive pulmonary fibrosis was cleared in China before the United States. AstraZeneca has also turned heads by rolling out “Taishizhuo,” the first biologic in China that treats severe asthma without the usual biomarker restrictions, and the only drug targeting a protein called TSLP for chronic sinus disease with nasal polyps. Experts say this opens a new therapeutic option for many patients who previously had few choices. The British firm is further deepening its roots with a new cell‑therapy innovation hub in Zhangjiang, offering everything from early‑stage research to clinical‑grade manufacturing under one roof. Together, these moves show how global pharma giants are embedding themselves in China’s fast‑growing biotech ecosystem, promising Chinese patients quicker access to the latest life‑saving treatments.
Read moreMedical‑device companies listed on China’s STAR Market are posting a 27% jump in first‑half revenue, and they’re doing it by selling more abroad. Firms such as United Imaging Healthcare now make over 90% of the key parts for their high‑end imaging and radiotherapy machines in‑house, while Beixin Life Sciences has rolled out China’s first home‑grown 60 MHz IVUS system – a device that not only earned EU‑MDR approval but is also gaining market share overseas. Other breakthroughs include MicroPort’s world‑first branched aortic stent graft and Sinomed’s FDA‑cleared intracranial drug‑eluting stent, both of which show Chinese firms can replace foreign technology in the most advanced clinical settings. Revenue numbers back up the hype. HybriTech Medical posted 1.53 billion RMB in sales, up 25.8% year‑on‑year, while Beixin’s precision PCI business grew 45% after its IVUS system entered provincial procurement lists. United Imaging’s overseas sales hit 1.77 billion RMB – a 54% jump – and now make up a quarter of its total revenue. Nanwei Medical earned 1.09 billion RMB abroad, representing 63% of its sales, and Haier Biomedical’s global business grew double‑digit percentages across Asia, the Americas and Africa. Analysts say the era of simple export and OEM contracts is over. Chinese med‑tech firms are now setting up local operations, pursuing cross‑border acquisitions and building end‑to‑end supply chains overseas. In short, the world is becoming the next big growth engine for China’s home‑grown medical‑device innovators.
Read moreShenzhen‑based Core Medical Technology has just cleared a major hurdle for its Corheart 6 artificial heart: the device earned the European Union’s CE‑MDR certification, the first time a Chinese‑made fully magnetic‑levitation heart pump has met Europe’s strict safety standards. The approval not only lets Core Medical sell the Corheart 6 across the EU and the European Economic Area, but also gives the product a “destination therapy” label – meaning it can be used as a permanent, long‑term solution for patients who cannot receive a donor heart. Heart failure affects millions worldwide, and donor shortages make artificial hearts an increasingly vital option. Until now, the market has been dominated by a handful of overseas giants. Corheart 6’s entry promises to break that monopoly, offering a home‑grown alternative that meets international quality benchmarks. Industry analysts predict the global artificial‑heart market will grow from about $1.2 billion in 2024 to over $4 billion by 2033, with implantation numbers expected to jump ten‑fold. With CE certification recognized in more than 50 countries and covering over two billion people, Core Medical’s breakthrough could bring new hope to heart‑failure patients around the world and spark a shift toward a more diversified, competitive market.
Read more